Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alemtuzumab - Bayer/Sanofi/University of Cambridge

Drug Profile

Alemtuzumab - Bayer/Sanofi/University of Cambridge

Alternative Names: Anti-CD52 monoclonal antibody; Campath; Campath-1H; LDP-03; Lemtrada; MabCampath; MabKampat; Remniq

Latest Information Update: 25 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Cambridge
  • Developer Bayer HealthCare Pharmaceuticals Inc.; Dana-Farber Cancer Institute; German CLL Study Group; Ohio State University Comprehensive Cancer Center; Sanofi; Sanofi Oncology; University of Cologne
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD52 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Multiple sclerosis
  • Phase II T-cell prolymphocytic leukaemia
  • Phase I Lymphoma
  • No development reported Diffuse large B cell lymphoma; Graft-versus-host disease; T-cell lymphoma
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 14 Jan 2019 Sanofi and Dana-Farber Cancer Institute terminates a phase I trial in Lymphoma in USA (NCT03132584)
  • 10 Oct 2018 Efficacy and safety data from the phase III/IV TOPAZ trial in Multiple Sclerosis presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2018)
  • 10 Oct 2018 Pooled efficacy and safety data from the phase III CARE-MS trials in Multiple Sclerosis presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top